Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/benazepril - Novartis

Drug Profile

Amlodipine/benazepril - Novartis

Alternative Names: Amlodipine besylate/benazepril hydrochloride; Lotrel

Latest Information Update: 25 Jun 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihypertensives; Benzazepines; Dihydropyridines; Ischaemic heart disorder therapies
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 16 Jun 2009 Efficacy data from the phase III ACCOMPLISH trial in Hypertension presented at the 19th European Meeting on Hypertension (ESH-2009)
  • 05 Dec 2008 Final efficacy and adverse events data from the phase III ACCOMPLISH trial in Hypertension released by Novartis
  • 01 Apr 2008 Interim efficacy data from the ACCOMPLISH trial for Hypertension presented at the 57th Annual Scientific Session of the American College of Cardiology (ACC-2008)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top